BPC-157: The Most-Studied Repair Peptide, Studied Almost Entirely in Rats

The short version

BPC-157 is a lab-made chain of 15 amino acids. Its sequence copies part of a protein found in human gastric juice — the fluid in the stomach — which is where the name Body Protection Compound comes from.

In animal experiments it speeds up healing in a wide range of tissues. The clearest explanation researchers have for that is angiogenesis: the growth of new blood vessels into an injured area, which brings the blood supply that repair depends on.

The catch is the size and species of the evidence. Nearly all of it is rat work. A 2025 review of BPC-157 for musculoskeletal healing counted only three pilot studies in humans and said outright that large, rigorous trials are lacking ^[2]. The single published intravenous safety study involved two people ^[1].

And for the specific question this site is built around: no study cited here measured whether BPC-157 heals bone or repairs cartilage in anyone. The nearest result is a cut tendon in a rat ^[6].

What it is

BPC-157 is a synthetic pentadecapeptide — fifteen amino acids, sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular formula C62H98N16O22. It is derived from a partial sequence of BPC, a protein present in human gastric juice, and it is described in the literature as a stable gastric pentadecapeptide. It circulates in research and commerce under several designations: Pentadecapeptide BPC 157, BPC 157, PL 14736, PLD-116 and PL-10.

Its regulatory position is unambiguous. It is not approved by the FDA, or by any other regulator, for human use. In 2023 the FDA placed BPC-157 in a category of bulk drug substances identified as not eligible for pharmacy compounding under section 503A, pending further evaluation. The World Anti-Doping Agency prohibits it at all times under the S0 non-approved-substances category. Suppliers sell it for laboratory research use only, and it has no established human therapeutic indication.

One further property matters for interpreting anything else. Formal pharmacokinetic work in rats and beagle dogs found linear pharmacokinetics, an elimination half-life under 30 minutes, intramuscular bioavailability of roughly 14–19% in rats and 45–51% in dogs, rapid breakdown into small peptide fragments that enter normal amino-acid metabolism, and excretion by urine and bile ^[3]. A compound cleared that fast is a poor fit for the mental model of a substance that lingers and slowly rebuilds a joint.

How it works

The best-characterised mechanism is vascular. BPC157 up-regulates expression of the VEGFR2 receptor and promotes its internalisation, activating the downstream VEGFR2–Akt–eNOS pathway. That work was done in the chick chorioallantoic membrane, in a rat hindlimb ischaemia model, and in human vascular endothelial cells, and it produced increased vessel density both in vivo and in vitro plus faster blood-flow recovery in ischaemic muscle; blocking endocytosis abolished the effect ^[4].

Several secondary routes are reported. The FAK–paxillin complex is implicated in cell migration. In cultured tendon cells, growth-hormone-receptor signalling is increased, which is one proposed reason tendon models respond. And a review positions BPC 157 as a brain-gut-axis mediator of Robert's cytoprotection that modulates nigrostriatal serotonin release and dopaminergic systems and engages Egr-1, NAB2, FAK-paxillin and JAK-2 pathways — a synthesis drawn from rodent central-nervous-system and gastrointestinal studies ^[7].

Read against the hard tissues, that mechanism set is suggestive and incomplete. Vascular supply is central to how bone heals; it is not how cartilage works, since articular cartilage is avascular and has almost no intrinsic repair capacity in adults. An angiogenic mechanism therefore offers no obvious route to cartilage restoration, and none of the cited experiments tested one.

What the research shows

The findings below are reported with the model species stated, because the species is the finding.

Gastric ulcer, Wistar rats. BPC 157 reduced gastric ulcer area and accelerated ulcer healing, with intramuscular delivery outperforming intragastric; ulcer-formation inhibition ratios were 45.7–65.6% at the higher doses studied, alongside faster rebuilding of glandular epithelium and granulation tissue ^[5]. This is the foundational cytoprotection result, and it is a stomach lining in a rat.

Transected Achilles tendon, Wistar rats, plus rat tendocytes in vitro. BPC 157 accelerated healing of a fully severed Achilles tendon across biomechanical, functional, microscopic and macroscopic measures, with better collagen organisation and restored tendon integrity versus untreated controls, and it stimulated tendocyte outgrowth in culture ^[6]. This is the closest study in the collection to hard tissue — and it is dense connective tissue, in a rat.

Angiogenesis, mixed models. Vessel density rose and ischaemic blood flow recovered faster, via VEGFR2 up-regulation and internalisation, in chick membrane, rat hindlimb and human endothelial cell systems ^[4].

Pharmacokinetics, rats and beagle dogs. Linear kinetics, elimination half-life under 30 minutes, intramuscular bioavailability approximately 14–19% in rats and 45–51% in dogs ^[3].

Humans, safety only. An intravenous safety pilot administered BPC-157 at up to 20 mg to two healthy adults — a 58-year-old man and a 68-year-old woman. It was well tolerated with no observed adverse events and no measurable change in cardiac, hepatic, renal, thyroid or glucose biomarkers ^[1]. With an n of two and no efficacy endpoint, this establishes that a dose was tolerated by two people. It establishes nothing about whether the compound works.

The review position. A 2025 narrative review concluded that despite broad preclinical support, human data are extremely limited — only three pilot studies — that rigorous large-scale trials are lacking, and that BPC-157 should be considered investigational and approached with caution given the regulatory controversy and non-regulated availability ^[2]. A 2026 sports-medicine review reached a compatible conclusion for the wider class: animal-model promise, scarce human safety data, potential for serious harm, largely outside regulatory oversight ^[8].

Reported effects, cautions and safety

What follows is anecdotal, not clinical evidence — self-reported experience gathered from research-use communities, peptide forums and clinic write-ups, with no controls, no blinding, no verification of what was actually in the vial, and no doses reported here.

On the benefit side, the most common report by a wide margin is faster recovery from tendon, ligament and joint injuries: stubborn problems such as tennis elbow, rotator-cuff strains and old sprains described as more usable within the first one to three weeks. Reduced joint stiffness and easier painful movement are frequently reported. Improved digestive symptoms — less bloating, cramping and urgency — are also frequently reported, which is unsurprising given the compound's gastric origin, though gastroenterologists point out no controlled human trial stands behind it. Reported less often: a general sense of reduced inflammation, faster closure of minor skin wounds, and better sleep or steadier mood. Commentators note that the last of those could equally reflect sleeping better because something hurts less, or placebo.

On the adverse side, injection-site redness, stinging or a small bump is very commonly reported and described as fading within a day. Nausea or mild stomach upset is frequently reported, more with oral or sublingual products than injections. Occasionally reported: first-week fatigue, headache, brief dizziness or light-headedness shortly after administration, and transient flushing or warmth. Rarely, users mention palpitations or a racing heartbeat; commentators treat persistent rapid heartbeat, chest pain or marked blood-pressure change as reasons to stop and seek medical evaluation.

Cautions from the literature. The human evidence is extremely thin — almost everything known comes from rodent studies, and the real balance of benefit and risk in people is genuinely unknown ^[2]. A large share of the foundational literature was produced by a single research group and its collaborators, so independent replication is limited, a point newer reviewers flag explicitly ^[2]. The compound is not an approved drug and moves through non-regulated channels, so identity, purity and actual content are unverified outside formal studies. Its strong pro-angiogenic activity ^[4] raises a mechanism-based theoretical concern for anyone with an active or suspected cancer, since tumours also depend on new blood vessels; this is reasoning from mechanism, not a human finding. Rodent work showing altered brain serotonin activity ^[7] is the basis of a theoretical interaction concern with serotonin-raising medicines, again untested in humans. Increased growth-hormone-receptor signalling in cultured tendon cells leaves an open question about long-term growth effects that no long-term human data can currently answer. It is prohibited at all times in sport. And it has never been studied in pregnancy, breastfeeding or children, where avoidance is the precautionary default.

Where it fits in bone, cartilage and hard-tissue repair

BPC-157 is the lead compound of this file because it has the largest literature, not because that literature reaches the hard tissues.

What it has: a coherent, mechanistically specific angiogenic story ^[4]; a genuinely striking tendon result in a rat, across four independent measurement types ^[6]; a foundational mucosal healing result, also in rats ^[5]; and pharmacokinetics characterised in two species ^[3].

What it does not have: a single controlled experiment in this collection with a bone or cartilage endpoint, in any species. No fracture model, no osteotomy, no chondral defect, no osteoarthritis outcome. The bone- and cartilage-repair claims that circulate around this compound are extrapolations from soft-tissue rodent work plus the general plausibility of an angiogenic mechanism — and cartilage, being avascular, is the tissue an angiogenic mechanism has the least obvious claim on.

Anyone reading this compound honestly ends up in the same place as the 2025 review: investigational, preclinically interesting, humanly unproven ^[2].